The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
Status:
Completed
Trial end date:
2016-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare HIV RNA expression and infection within resting
(CD4)+ cells in HIV-infected patients on stable ART before and after a single exposure to
Vorinostat (VOR), after exposure to short intervals of VOR, and after repeated short interval
exposure to VOR dosed over several weeks.
Hypotheses:
1. The frequency of resting CD4+ T cell- associated HIV RNA (RCVL) will be increased
following single and repeated exposure to VOR when given at appropriate intervals, and
2. That repeated exposure to VOR will reduce the frequency of HIV infection within resting
CD4+ T cells (RCI)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
Merck Sharp & Dohme Corp. National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH)